Missed NeoGenomics' Rally? Here Is What Holders Saw

If you had bought NeoGenomics back in early November 2025, the decision might feel very different today. Investors who held NeoGenomics over the past year are up 64.4%, including dividends. That outcome now sits alongside fresh headlines about strong Q3 2026 results, new Medicare coverage for RaDaR ST, an FDA-approved PTEN companion diagnostic, and a CEO transition. If you were weighing the stock back then, which signals would have mattered most?

NeoGenomics is not the only name tied to this theme. Zero in on 38 healthcare AI stocks and compare how each one is priced.

The Two NeoGenomics Stories Investors Had To Weigh

The shares cost US$10.1 at the start of the period, and NeoGenomics sat between two very different but plausible paths.

The bullish narrative pointed to a Fair Value of US$14, a rough guide to what supporters thought the stock could be worth if their thesis played out, built on revenue growth assumptions of 10.7% a year and a future profit margin reaching 5.3%.

The bearish view anchored to a Fair Value of US$6.5, based on slower 8.5% annual revenue growth and concern that persistent pharma services weakness and execution issues could keep demand and earnings under pressure.

What The Results Changed For The NeoGenomics Thesis

Medicare coverage for RaDaR ST and the FDA cleared PTEN companion test gave NeoGenomics concrete wins for the bullish case that higher value oncology assays could support revenue. Reported figures backed that up, since total revenue moved from US$187.8m in Q3 2025 to US$209.3m in Q3 2026 and the net loss narrowed. Profitability still remained negative, so the full optimistic margin story stayed unproven. Overall, the evidence cut both ways.

The key assumption here was that a richer testing mix and new diagnostics would translate into cleaner economics. For another diagnostics stock, you would track the combination of product approvals, reimbursement decisions, absolute profit, and the reported net margin line to see whether that same claim is actually turning into progress.

What NeoGenomics' Repricing Asks You To Believe Now

Today NeoGenomics trades at US$17.15, and the selected Narrative’s Fair Value sits above the current price based on its own framework rather than hard fact. That view leans heavily on the idea that higher value oncology testing and better efficiency can support stronger profitability over time.

The Narrative hangs on a simple question for anyone paying today’s price. Do you believe NeoGenomics can keep scaling new liquid biopsy and MRD offerings while cost investments translate into meaningfully higher margins rather than just higher complexity?

"Investments in new digital pathology capabilities, automation, and the integration of a unified LIMS are expected to generate material operating efficiencies and enable greater operating leverage, supporting future expansion in EBITDA margins and earnings growth."

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for

Before The Next Story Makes Headlines

The story behind this run has already been told. The next one could be taking shape somewhere else. Where could you start looking before it becomes the headline?

• Company 1 - 25% below our estimate - embeds AI tools into everyday productivity suites for large organizations.
• Company 2 - 41% below our estimate - scales modular LED display systems as venues modernize and expand visual experiences.
• Company 3 - 34% below our estimate - ships lidar hardware into long-term vehicle programs moving beyond limited pilots.

Three companies from the same screener. Open all 35 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com